Top Markets
#1 Pleasing Gold Pleasing Gold +1,510.61%
#2 Ontology Gas Ontology Gas +96.40%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +33.22%
#5 BOOK OF MEME BOOK OF MEME +32.36%
#6 Neiro Neiro +30.17%
#7 Collect on Fanable Collect on Fanable +29.35%
#8 Unit Pump Unit Pump +28.42%
#9 Pump.fun Pump.fun +28.42%
#10 Ontology Ontology +25.90%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rangering i aksjer #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aksjekurs
$15.31
Sist synkronisert: 2024-02-29
Markedsverdi
$45.70M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Icosavax, Inc. (ICVX)

Kategori

Healthcare
Inntekter for Icosavax, Inc. (ICVX)
Inntekter i 2026 TTM: 0
Ifølge Icosavax, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Icosavax, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US